Literature DB >> 21051859

Defining the E-cadherin repressor interactome in epithelial-mesenchymal transition: the PMC42 model as a case study.

Honor J Hugo1, Maria I Kokkinos, Tony Blick, M Leigh Ackland, Erik W Thompson, Donald F Newgreen.   

Abstract

Epithelial-mesenchymal transition (EMT) is a feature of migratory cellular processes in all stages of life, including embryonic development and wound healing. Importantly, EMT features cluster with disease states such as chronic fibrosis and cancer. The dissolution of the E-cadherin-mediated adherens junction (AJ) is a key preliminary step in EMT and may occur early or late in the growing epithelial tumour. This is a first step for tumour cells towards stromal invasion, intravasation, extravasation and distant metastasis. The AJ may be inactivated in EMT by directed E-cadherin cleavage; however, it is increasingly evident that the majority of AJ changes are transcriptional and mediated by an expanding group of transcription factors acting directly or indirectly to repress E-cadherin expression. A review of the current literature has revealed that these factors may regulate each other in a hierarchical pattern where Snail1 (formerly Snail) and Snail2 (formerly Slug) are initially induced, leading to the activation of Zeb family members, TCF3, TCF4, Twist, Goosecoid and FOXC2. Within this general pathway, many inter-regulatory relationships have been defined which may be important in maintaining the EMT phenotype. This may be important given the short half-life of Snail1 protein. We have investigated these inter-regulatory relationships in the mesenchymal breast carcinoma cell line PMC42 (also known as PMC42ET) and its epithelial derivative, PMC42LA. This review also discusses several newly described regulators of E-cadherin repressors including oestrogen receptor-α and new discoveries in hypoxia- and growth factor-induced EMT. Finally, we evaluated how these findings may influence approaches to current cancer treatment.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21051859     DOI: 10.1159/000320174

Source DB:  PubMed          Journal:  Cells Tissues Organs        ISSN: 1422-6405            Impact factor:   2.481


  38 in total

1.  miR-495 promotes the chemoresistance of SCLC through the epithelial-mesenchymal transition via Etk/BMX.

Authors:  Ting Wei; Weiliang Zhu; Shun Fang; Xiangpin Zeng; Jie Huang; Jie Yang; Jian Zhang; Linlang Guo
Journal:  Am J Cancer Res       Date:  2017-03-01       Impact factor: 6.166

2.  Contribution of Fibroblast and Mast Cell (Afferent) and Tumor (Efferent) IL-6 Effects within the Tumor Microenvironment.

Authors:  Honor J Hugo; Stephanie Lebret; Eva Tomaskovic-Crook; Nuzhat Ahmed; Tony Blick; Donald F Newgreen; Erik W Thompson; M Leigh Ackland
Journal:  Cancer Microenviron       Date:  2012-02-08

Review 3.  Epithelial-to-mesenchymal and mesenchymal-to-epithelial transitions in the colon.

Authors:  Ferenc Sipos; Orsolya Galamb
Journal:  World J Gastroenterol       Date:  2012-02-21       Impact factor: 5.742

Review 4.  Regulatory networks defining EMT during cancer initiation and progression.

Authors:  Bram De Craene; Geert Berx
Journal:  Nat Rev Cancer       Date:  2013-02       Impact factor: 60.716

Review 5.  Epithelial-mesenchymal transition transcription factors and miRNAs: "Plastic surgeons" of breast cancer.

Authors:  Caroline Moyret-Lalle; Emmanuelle Ruiz; Alain Puisieux
Journal:  World J Clin Oncol       Date:  2014-08-10

6.  Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions.

Authors:  Alejandro Vazquez-Martin; Eugeni López-Bonetc; Sílvia Cufí; Cristina Oliveras-Ferraros; Sonia Del Barco; Begoña Martin-Castillo; Javier A Menendez
Journal:  Drug Resist Updat       Date:  2011-05-19       Impact factor: 18.500

7.  Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin).

Authors:  Cristina Oliveras-Ferraros; Bruna Corominas-Faja; Sílvia Cufí; Alejandro Vazquez-Martin; Begoña Martin-Castillo; Juan Manuel Iglesias; Eugeni López-Bonet; Ángel G Martin; Javier A Menendez
Journal:  Cell Cycle       Date:  2012-09-19       Impact factor: 4.534

8.  Promoter hypomethylation of EpCAM-regulated bone morphogenetic protein gene family in recurrent endometrial cancer.

Authors:  Ya-Ting Hsu; Fei Gu; Yi-Wen Huang; Joseph Liu; Jianhua Ruan; Rui-Lan Huang; Chiou-Miin Wang; Chun-Liang Chen; Rohit R Jadhav; Hung-Cheng Lai; David G Mutch; Paul J Goodfellow; Ian M Thompson; Nameer B Kirma; Tim Hui-Ming Huang
Journal:  Clin Cancer Res       Date:  2013-09-27       Impact factor: 12.531

Review 9.  Mechanisms of vasculogenic mimicry in hypoxic tumor microenvironments.

Authors:  Xiaoxu Wei; Yunhua Chen; Xianjie Jiang; Miao Peng; Yiduo Liu; Yongzhen Mo; Daixi Ren; Yuze Hua; Boyao Yu; Yujuan Zhou; Qianjin Liao; Hui Wang; Bo Xiang; Ming Zhou; Xiaoling Li; Guiyuan Li; Yong Li; Wei Xiong; Zhaoyang Zeng
Journal:  Mol Cancer       Date:  2021-01-04       Impact factor: 27.401

10.  Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets.

Authors:  Steven J Van Laere; Naoto T Ueno; Pascal Finetti; Peter Vermeulen; Anthony Lucci; Fredika M Robertson; Melike Marsan; Takayuki Iwamoto; Savitri Krishnamurthy; Hiroko Masuda; Peter van Dam; Wendy A Woodward; Patrice Viens; Massimo Cristofanilli; Daniel Birnbaum; Luc Dirix; James M Reuben; François Bertucci
Journal:  Clin Cancer Res       Date:  2013-02-08       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.